Clinical trial
Interleukin-12, Paclitaxel, and Trastuzumab in Treating Patients With Solid…
NCT00028535 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00028535 |
|---|---|
| Title | Interleukin-12, Paclitaxel, and Trastuzumab in Treating Patients With Solid Tumors |
| Official title | Phase I Trial of Interleukin-12 in Combination With Paclitaxel Plus Herceptin in Patients With Her2-positive Malignancies |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Male Breast Cancer, Recurrent Breast Cancer, Recurrent Endometrial Carcinoma, Recurrent Gastric Cancer, Recurrent Non-small Cell Lung Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Small Cell Lung Cancer |
| Intervention type | Biological, Drug |
| Interventions | trastuzumab, paclitaxel, recombinant interleukin-12 |
| Enrollment | 18 |
| Start date | Nov 1, 2001 |
| Primary completion | Feb 1, 2009 |
| First posted | Jan 27, 2003 |
| Last update posted | Jun 4, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: